Oral 11β-HSD1 inhibitor AZD4017 improves wound healing and skin integrity in adults with type 2 diabetes mellitus: a pilot randomized controlled trial.

ABSTRACT:

Background

Chronic wounds (e.g. diabetic foot ulcers) reduce the quality of life, yet treatments remain limited. Glucocorticoids (activated by the enzyme 11β-hydroxysteroid dehydrogenase type 1, 11β-HSD1) impair wound healing.

Objectives

Efficacy, safety, and feasibility of 11β-HSD1 inhibition for skin function and wound healing.

Design

Investigator-initiated, double-blind, randomized, placebo-controlled, parallel-group phase 2b pilot trial.

Methods

Single-center secondary care setting. Adults with type 2 diabetes mellitus without foot ulcers were administered 400 mg oral 11β-HSD1 inhibitor AZD4017 (n = 14) or placebo (n = 14) bi-daily for 35 days. Participants underwent 3-mm full-thickness punch skin biopsies at baseline and on day 28; wound healing was monito

SUBMITTER: Ajjan RA 

PROVIDER: S-EPMC8942338 | biostudies-literature | 2022 Feb

REPOSITORIES: biostudies-literature